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Abstract
Chronic lung disease of prematurity/bronchopulmonary dysplasia (BPD) is
the leading cause of perinatal morbidity in developed countries. Inflammation
is a prominent finding. Currently available interventions have associated toxi-
cities and limited efficacy. While BPD often resolves in childhood, survivors
of preterm birth are at risk for acquired respiratory disease in early life and
are more likely to develop chronic obstructive pulmonary disease (COPD) in
adulthood. We previously cloned Crispld2 (Lgl1), a glucocorticoid-regulated
mesenchymal secretory protein that modulates lung branching and alveogene-
sis through mesenchymal–epithelial interactions. Absence of Crispld2 is
embryonic lethal. Heterozygous Crispld2+/ mice display features of BPD,
including distal airspace enlargement, disruption of elastin, and neonatal lung
inflammation. CRISPLD2 also plays a role in human fetal lung fibroblast cell
expansion, migration, and mesenchymal–epithelial signaling. This study
assessed the effects of endogenous and exogenous CRISPLD2 on expression of
proinflammatory mediators in human fetal and adult (normal and COPD)
lung fibroblasts and epithelial cells. CRISPLD2 expression was upregulated in
a lipopolysaccharide (LPS)-induced human fetal lung fibroblast line (MRC5).
LPS-induced upregulation of the proinflammatory cytokines IL-8 and CCL2
was exacerbated in MRC5-CRISPLD2knockdown cells. siRNA suppression of
endogenous CRISPLD2 in adult lung fibroblasts (HLFs) led to augmented
expression of IL-8, IL-6, CCL2. LPS-stimulated expression of proinflammatory
mediators by human lung epithelial HAEo- cells was attenuated by purified
secretory CRISPLD2. RNA sequencing results from HLF-CRISPLD2knockdown
suggest roles for CRISPLD2 in extracellular matrix and in inflammation. Our
data suggest that suppression of CRISPLD2 increases the risk of lung inflam-
mation in early life and adulthood.
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
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Introduction
Preterm birth affects 12.5% of pregnancies in the United
States, and this rate continues to increase (Goldenberg
et al. 2008). Chronic lung disease of infancy-bronchopul-
monary dysplasia (BPD) affects up to 43% of infants born
at <1500 g (Stoll et al. 2010). BPD is the leading cause of
perinatal morbidity in developed countries. While BPD
often resolves in childhood, survivors of preterm birth
require increased hospitalization for acquired respiratory
disease in early life and are more likely to develop chronic
obstructive pulmonary disease (COPD) in adulthood
(Kramer et al. 2009). Unfortunately, for the prevention or
treatment of BPD, the few interventions currently avail-
able (such as mechanical ventilation, oxygen therapy,
nutritional support, and corticosteroid therapy) are of
limited efficacy (Allen et al. 2003; Wright and Kirpalani
2011) and are associated with significant toxicities.
The prominent pulmonary pathological manifestations
of infants dying from BPD are: arrested alveogenesis, air-
way inflammation, and parenchymal fibrosis (Jobe and
Bancalari 2001). Lung inflammation associated with pre-
natal chorioamnionitis and postnatal respiratory tract
infections is associated with disease progression (Allen
et al. 2003). Proinflammatory cyto-/chemokine factors,
present in the air spaces of ventilated preterm infants, are
increased in the air spaces of infants who subsequently
develop BPD. In a prospective cohort study of 1067 pre-
term infants, of whom 606 developed BPD, an early
increase in IL-8 and IL-6 levels predicted BPD (Ambala-
vanan et al. 2009). In transgenic mice, overexpression of
the proinflammatory mediators TNF-a, TNF-b, IL-6, and
IL-1b interferes with alveolarization, suggesting that the
proinflammatory environment of the air space of the pre-
term infant may contribute to the arrest in BPD of the
secondary septation involved in alveolar formation (Jobe
and Bancalari 2001). Although inflammation is essential
to the pathogenesis of BPD, to this date, this understand-
ing has not translated into useful therapies (Watterberg
2010; Wright and Kirpalani 2011). Glucocorticoids (GCs)
have serious side effects, including aggravation of pul-
monary developmental arrest, gastrointestinal perforation,
cardiac hypertrophy, short- and long-term systemic
growth failure, and serious neurodevelopmental delay
(Jobe and Bancalari 2001; Bassler et al. 2015). A better
understanding of the inflammatory regulators involved in
the pathogenesis of the disease will be important in find-
ing effective new therapies for BPD.
We previously identified and cloned CRISPLD2 (which
we originally called late gestation lung 1, LGL1), a GC-
and developmentally regulated gene encoding a secreted
mesenchymal protein in the lung and other organs (Himes
et al. 2014). CRISPLD2 modulates both airway branching
morphogenesis and alveogenesis through mesenchymal–
epithelial interactions (Oyewumi et al. 2003b; Nadeau
et al. 2006; Lan et al. 2009). Expression of Crispld2 can be
directly upregulated by GC in primary rat fetal lung
fibroblasts (Kaplan et al. 1999). Absence of Crispld2 in
null mice is lethal in early embryogenesis. Heterozygous
Crispld2+/ mice have features that resemble human
BPD, including distal airspace enlargement, disruption of
elastin, and signs of neonatal lung inflammation (includ-
ing goblet cell hyperplasia) and elevated expression of
proinflammatory mediators (Lan et al. 2009).
Lung fibroblasts are involved in developmental airway
remodeling as well as in tissue repair following inflamma-
tory injury of small airways (Chapman 2011). Recently,
we showed that CRISPLD2 regulates lung fibroblast pro-
liferation and apoptosis, and lung epithelial cell migration
through mesenchymal–epithelial interactions. These find-
ings confirmed a functional role for CRISPLD2 in lung
epithelial maturation (Zhang et al. 2015). In this study
we explored the role of CRISPLD2 in inflammation in
fetal and adult lung fibroblasts. CRISPLD2 is a cystine-
rich secreted protein (CRISP), characterized by a secretory
signal and two LCCL domains. The LCCL domain, previ-
ously identified in horseshoe crab Limulus factor, binds to
lipopolysaccharide (LPS, the immunostimulatory compo-
nent of gram-negative bacteria), is protective against
endotoxin, and is involved in antibody-independent host
defense (Trexler et al. 2000; Gibbs et al. 2008).
This study used genetic silencing of CRISPLD2 and
recombinant CRISPLD2 (rCRISPLD2) protein to investi-
gate the effect of endogenous and exogenous CRISPLD2
on the expression and secretion of the proinflammatory
cyto/chemokines IL-8 and CCL2 by human fetal lung
fibroblasts (MRC-5), adult primary lung fibroblasts
(HLF), and airway epithelial (HAEo-) cells. Our findings
suggest that CRISPLD2 serves as an endogenous antiin-
flammatory gene in lung fibroblasts that also curtails
proinflammatory signaling by lung epithelial cells through
mesenchymal–epithelial interactions. These data support
the hypothesis that inhibition of CRISPLD2 increases the
risk of lung inflammation in early life and in adulthood.
To begin to explore the potential role of CRISPLD2 in
adult lung disease, we investigated CRISPLD2 expression
in lung fibroblasts isolated from controls and from COPD
patients. Recent advances in sequencing technologies have
made possible comprehensive and in-depth characteriza-
tion of transcriptomes using RNA-seq (Ozsolak and Milos
2011). We therefore used RNA-seq to characterize tran-
scriptomic changes following knockdown of CRISPLD2 in
each of the cell lines. We identified differentially
expressed genes in normal and in COPD lung fibroblasts
representing functional categories including cellular
response to hormone stimulation (steroid hormone and
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insulin signaling pathway, cAMP mediated pathway), che-
mokine signaling pathway, development, regulation of cell
migration, and extracellular matrix regulation.
Materials and Methods
Lentiviral transduction of short hairpin RNA
(shRNA) CRISPLD2 in MRC-5 cells
Human fetal lung fibroblasts, MRC5 (ATCC, Manassas,
VA), grown in minimal essential medium (MEM) (Wisent,
Montreal, QC, Canada) with 10% (v/v) FBS and 1% peni-
cillin/streptomycin, were used between passages 5–15, such
that studies were completed before the MRC-5 cells enter
senescence. CRISPLD2 shRNA constructs, and a scrambled
shRNA used as a negative control, were cloned into a
pTRIPZ lentiviral doxycycline (DOX)-inducible vector
(Thermo, Ottawa, ON, Canada). Lentivirus was produced
by transfecting 293T cells with shRNA constructs pVSV-G
and psPAX2 using lipofectamine 2000 (Life technology,
Burlington, ON, Canada). MRC-5 cells were infected with
lentivirus and puromycin (0.5 lg/mL) (Wisent) was added
after 48 h to select stable clones. The characterization of
MRC5CRISPLD2KD has been described in detail previously
by Zhang et al. (2015). Suppression of CRISPLD2 protein
levels in MRC5CRISPLD2KD cells after 4 days DOX induc-
tion was confirmed by western blot analysis. CRISPLD2
was suppressed by DOX induction only in
MRC5CRISPLD2KD and not in MRC5control cells. All further
experiments were carried out using 2 lg/mL DOX induc-
tion for 4 days in MRC5CRISPLD2KD cells. The suppression
of CRISPLD2 mRNA in MRC5CRISPLD2KD cultures was
repeatedly confirmed prior to each set of experiments.
Primary human lung fibroblast cell culture
and siRNA transfection
Primary cultured human airway fibroblasts (HLF) were
prepared from second to fourth generation peripheral
lung tissue in resected specimens. All procedures were
approved by the Human Research Ethics Board (Univer-
sity of Manitoba) and all donors gave informed consent.
As described in detail (Ghavami et al. 2010; Sharma et al.
2015), after microdissection to separate the lamina reticu-
laris and submucosal compartment from encircling airway
smooth muscle bundle, HLF were isolated by enzymatic
dissociation. For all experiments, passage 3–7 of HLF
were used and cells were cultured in fibroblast medium
(Sciencell Research Laboratories, Carlsbad, CA). The med-
ium was changed every 48 h. Transfection of CRISPLD2
siRNA and nontargeting siRNA (negative control) (siRNA
universal non-targeting control 1, Sigma-Aldrich Corpo-
ration, St. Louis, MO) was performed using DharmaFECT
1 reagent according to the manufacturer’s recommended
protocol (Thermo Scientific, Lafayette, CO). The final
concentration of siRNA was 25 nmol/L; siRNA sequences
for CRISPLD2 knockdown were as follows: 50-GAAC-
CAACAUCUAUGCAGA(dT)(dT)-30 and 50-UCUG-
CAUAGAUCUUGGUUC(dT)(dT)-3. Primary HLF cells
from five normal and five COPD patients (GOLD classifi-
cation) are used for siRNA transfection. The suppression
of CRISPLD2mRNA in HLF cultures was confirmed prior
to each set of experiments.
RNA-seq library construction and
sequencing
Total RNA was extracted from normal (Norm) and
COPD HLF cells using the miRNAeasy mini kit (QIA-
GEN Inc.,Toronto, ON). A quantity of 1 mg of RNA
from each sample was used to generate RNA-seq cDNA
libraries for sequencing using TruSeq Stranded Total
RNA Library Prep Kit (Illumina Inc., San Diego, CA).
RNA-seq data analysis
We performed RNA-seq transcriptome profiling of fibro-
blasts from four normal (age: 65–77 years, male) and four
COPD human patients (age: 58–68 years, male, moderate-
severe COPD, GOLD classification), which are individually
transfected with siRNA negative control or CRISPLD2
knockdown, in technical duplicates. The reads from resulting
RNA-seq output FASTQ files were trimmed of the TruSeq
adapter sequences using Skewer (Jiang et al. 2014) with
default parameters. FastQC (http://www.bioinformat-
ics.babraham.ac.uk/projects/fastqc/) was used to visualize
Phred quality scores for initial quality control. The trimmed
reads were aligned against the primary assembly of the
human genome version GRCh38 (http://www.ncbi.nlm.nih.-
gov/projects/genome /assembly/grc/human/) concatenated
with ERCC RNA Spike-In mix 1 (Thermo Fisher Scientific
Inc, Waltham, MA) FASTA files using STAR aligner (Dobin
et al. 2013) to create a BAM file (https://samtools.github.io/
hts-specs/SAMv1.pdf) for each sample. Mapping rates and
other quality control metrics suggested a high level of
sequencing quality. The CuffNorm tool in Cufflinks (Trap-
nell et al. 2012) was used to synthesize the BAM files into the
count data matrix D of 65,972 genes 932 samples. We per-
formed subsequent bioinformatics analyses on the quantile
normalized data matrix log2(D + 10). Wilcoxon rank-sum
test was used to assess differential expression of a gene
between negative control and CRISPLD2 knockdown sam-
ples in the healthy and COPD patient groups separately. A
gene was considered significantly differentially expressed
when its rank-sum P-value was <0.05 and the log2 fold
change magnitude >1 (twofold in linear scale). Gene
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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ontology analysis of sets of significantly differentially
expressed genes was performed using DAVID 6.7(da Huang
et al. 2009) .
CRISPLD2-open reading frame (ORF) protein
purification
Cloning and recombinant expression of human
CRISPLD2 in HEK293 cells
The human CRISPLD2 ORF cDNA was cloned into the vec-
tor pIRES2 (Clontech, Palo Alto, CA) with the green fluores-
cent protein (GFP) and V5 and His tags. GFP not fused to
the inserted protein allows monitoring of transfection effi-
ciency. V5 fused to the inserted protein before the stop
codon allows for identification of the inserted protein. His
tag is fused to the inserted protein after V5 and before the
stop codon. HEK293 cells were transfected with human
CRISPLD2 ORF plasmid or empty vector using lipofec-
tamine 2000. After 48 h, G418 600 lg/mL was added for
selection. After 2 weeks, stable cell clones from single cells
were used. Protein expression of CRISPLD2 in HEK293control
(containing empty vector) and HEK293CRISPLD2ORF cell
lysates and media were examined by western blot using the
V5 antibody as previously reported by Zhang et al. (2015).
The stable cell line HEK293-CRISPLD2-HIS-V5 was main-
tained in Dulbecco’s modified eagle’s medium (DMEM)
with 10% (v/v) heat-inactivated (56°C 30 min) fetal bovine
serum, 1% penicillin/streptomycin, and 600 lg/mL G418
(Life Technologies, Carlsbad, CA). The cells were passaged
1:3 when they reached 95% density. The cells were expanded
into three 225 cm2 Corning Flasks (Corning Inc., Acton,
MA) to get enough supernatant for purification. When they
were 80% confluent, DMEM (serum-free, antibiotic-free)
medium was added carefully after washing the flasks twice
with PBS, and cultured for 48 h. Cell culture supernatant
was collected for detection and purification.
Preparation of rCRISPLD2
Cell culture broth was centrifuged and loaded onto Ni
SephoroseTM6 Fast Flow 0.5 mL (GE, Mississauga, ON,
Canada) at 1.0 mL/min. After washing and elution with
appropriate buffer, the eluted fractions were pooled and
buffer exchanged to PBS, pH = 7.2. The purified protein
was analyzed by SDS-PAGE and western blot.
Purified protein activity assessment by migration
assay
Transwell migration assays were performed according to
the manufacturer’s protocol (BD Bioscience, Mississauga,
ON, Canada). The human tracheal epithelial cell line
(1HAEo-) was a kind gift from Dr. Dieter Gruenert
(University of California at San Francisco) (Cozens et al.
1992). 1HAEo- cells were grown in MEM medium con-
taining 2 mmol/L L-glutamine with 10% (v/v) FBS and
1% penicillin/streptomycin. For the migration assay,
serum-free medium containing 1.25 9 104 1HAEo- cells
were placed on transwell membranes (8.0 lm). The
transwell inserts were placed in a 24-well plate
filled with medium containing various amounts of
rCRISPLD2 for 18 h. Conditioned medium collected
from HEK293CRISPLD2ORF were used as positive control
(PC). Medium without rCRISPLD2 was used as negative
control. Cells that passed through the membranes were
fixed, stained and then assessed and counted under light
microscopy. Each condition was tested in three separate
wells of three individual experiments. For each experi-
ment, cell viability was assessed by trypan blue exclusion
before use in assays.
Real-time quantitative polymerase chain
reaction (qRT-PCR)
mRNA was assessed by qRT-PCR as described (Zhang et al.
2015). Briefly, RNA was isolated from cells using Trizol
(Life Technology) according to the manufacturer’s proto-
col. Quantitative real-time PCR was performed on the
LightCycler 480 (Roche, Indianapolis, IN) with SYBR green
master mix (Roche). Gene-specific primers used for SYBR
green detection of genes were as follows: Human
CRISPLD2-F, CCATGTTTGGCTCCAACCGA; Human
CRISPLD2-R, TGGGCAC TGGTACCTGTTACA; Human
IL-8-F, GAGTGGACCACACTGCGCCAA; Human IL-8-R,
TCCACAACCCTCTGCACCCAGTT; Human IL-6-F, ATT
CGGTACATCCT CGAC; Human Human IL-6-R, TGA
TGATTTTCACCAGGC; Human CCL-2-F, CTCATAGCA
GCCACCTTCAT; Human CCL-2-R, TGCTGCTGGTGA
TTCTTCTA, Human GAPDH-F, GAGTCCACTGGCG
TCTTCA; Human GAPDH-R, GGGGTGCTAAG-
CAGTTGGT. GAPDH was used as a housekeeping gene.
Relative mRNA expression levels were analyzed using the
DD cycle threshold method (n ≥ 4 for all assays).
Immunoblotting
Proteins in cell lysate and supernatants (50 lg) were
separated by SDS-PAGE and transferred to PVDF
membranes. Primary antibodies rabbit anti-CRISPLD2
(1:1000, Thermo Fisher Scientific) and rabbit-anti-actin
(1:6000, Santa Cruz Biotechnology, Dallas, TX)
were used as previously described by Zhang et al.
(2015).
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ELISA
IL-8 secretion in cell-free supernatants was assessed with
a commercial human IL8 ELISA kit (R&Dsystems, Min-
neapolis, MN) according to the manufacturer’s instruc-
tions.
Statistical analysis
All results are presented as mean  SEM. One-way
analysis of variance (ANOVA), followed by post hoc
analysis with Tukey’s test was used for determining the
significance of the differences in mean values among
more than two groups. Two-way ANOVA was used, as
stated in the Figure Legends, for two factors compari-
son. Student’s t test was used to compare only one fac-
tor between two groups (Prism, GraphPad, La Jolla,
CA). Statistical differences were considered significant at
P < 0.05.
Results
CRISPLD2 expression in MRC5 cells is
increased after LPS stimulation
LPS induces lung inflammation (Eutamene et al. 2005).
To determine if LPS induces inflammation in fetal lung
fibroblasts, MRC-5 cells were treated with LPS at 1 lg/
mL for 6 h and 24 h. Levels of IL-6 and IL-8, examined
by q-PCR, were significantly upregulated after LPS treat-
ment, suggesting that LPS can induce inflammation in
MRC-5 cells (Fig. 1A). Under the same conditions, signif-
icant upregulation of CRISPLD2 at both transcriptional
and protein levels by LPS was shown by q-PCR (Fig. 1B)
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Figure 1. Lipopolysaccharide (LPS) stimulation increased the expression of CRISPLD2 in MRC-5 cells. MRC-5 cells were treated by LPS (1 lg/mL)
for 6 h and 24 h. Cells were harvested at indicated time points and mRNA expression of IL-8 and IL-6 (A), and CRISPLD2 (B), were determined
by q-PCR and normalized to GAPDH (n = 4,*P < 0.05, **P < 0.01 vs. 0 h). C: CRISPLD2 protein levels at 0 h and 24 h after LPS treatment
were determined by western blot with anti-CRISPLD2 antibody, and normalized to ACTIN (n = 3,* P < 0.05).
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and western blot (Fig. 1C), suggesting a role for
CRISPLD2 in fetal lung fibroblast inflammation.
Suppression of CRISPLD2 augments LPS-
induced inflammation in MRC5 cells
To determine how CRISPLD2 modulates LPS-induced
inflammation in human fetal lung fibroblasts, DOX-indu-
cible CRISPLD2 shRNA was used to knockdown the
expression of endogenous CRISPLD2 in MRC-5.
CRISPLD2 expression was reduced by DOX induction for
4 days to 30% in MRC5 CRISPLD2KD as compared with
MRC5 control. Proinflammatory factors IL-8 and CCL-2,
were examined in both MRC5 control and MRC5 CRISPLD2KD
following LPS treatment at 1 lg/mL for 24 h. As shown in
Figure 2A, the increased levels of proinflammatory factors
IL-8 and CCL-2 mRNA expression in MRC5control cells
upon LPS induction is augmented in MRC-5CRISPLD2KD.
By ELISA, secreted IL-8 protein from cells was also
increased in MRC5 control supernatant upon LPS induction,
and this effect was augmented in MRC5 CRISPLD2KD
supernatant (Fig. 2B). This result suggests that endogenous
CRISPLD2 in fetal lung fibroblasts exerts an antiinflamma-
tory effect by controlling the levels of proinflammatory
cytokines.
Recombinant CRISPLD2 inhibited LPS-
induced inflammation in human airway
epithelial 1HAEo- cells
Longitudinally, mesenchymal–epithelial interactions not
only modulate fetal airway branching and postnatal alveo-
genesis in lung development but also contribute to the
pathogenesis of pulmonary fibrosis and COPD in adult-
hood due to epithelial–mesenchymal transition (Chapman
2011). Among the mediators involved in mesenchymal–
epithelial interactions in the lung, the spatial localization
of CRISPLD2-secreting myofibroblasts (Nadeau et al.
2006) points to a role for Crispld2 in fibroblast-epithelial
communication. To test whether secreted mesenchymal
CRISPLD2 regulates inflammation in lung airway epithe-
lial (1HAEo-) cells, recombinant CRISPLD2_ORF
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Figure 2. Suppression of CRISPLD2 in MRC5CRISPLD2KD exacerbated lipopolysaccharide (LPS)-induced inflammation. MRC5CRISPLD2KD and
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(rCRISPLD2) protein was purified from HEK293
CRISPLD2-conditioned medium and the activity of
rCRISPLD2 after purification was validated. Assessing the
dosage and toxicity of rCRISPLD2, 1HAEo- cells were ini-
tially incubated with rCRISPLD2 at 10, 50, 100, 125 ng,
or 250 ng/mL for either 24 h or 48 h. Cell morphology
and cell number were compared with untreated cells. No
effect of rCRISPLD2 on cell morphology and cell death
was observed in rCRISPLD2 concentrations ranging from
10 to 100 ng/mL. This dosage range was selected for fur-
ther validation of protein activity, avoiding the potential
toxic effects associated with higher protein dosage. We
validated rCRISPLD2 protein activity by transwell migra-
tion assay. CRISPLD2-conditioned medium promoted
1HAEo- cell migration through transwell membranes,
consistent with our previous findings (Zhang et al. 2015).
As shown in Figure 3A, 10, 50 ng, 100 ng/mL of
rCRISPLD2 promotes migrated cells through the transwell
membrane as compared to untreated cells in a dose-
dependent manner, supporting the preservation of protein
function or activity in purified rCRISPLD2 protein. We
used previously validated CRISPLD2-conditioned medium
as a positive control.
In order to evaluate the effect of rCRISPLD2 on LPS-
induced inflammation in lung airway epithelial cells,
1HAEo- cells were treated for 24 h with or without LPS
2.5 lg/mL, plus 0, 10, 20 ng, or 50 ng/mL of rCRISPLD2.
By ELISA, rCRISPLD2 inhibited LPS-induced IL-8 pro-
tein secretion from lung epithelial cells in a dose-depen-
dent manner (Fig. 3B). These results support an
antiinflammatory effect of exogenous CRISPLD2 on lung
epithelial cells and suggest that CRISPLD2 can reduce
proinflammatory signaling by lung epithelial cells through
mesenchymal–epithelial interactions.
Knockdown of CRISPLD2 augmented the
expression of proinflammatory mediators in
primary adult human lung fibroblast cell
lines
Initially, we characterized endogenous expression of
CRISPLD2mRNA in five primary normal HLFs and in
five primary COPD HLFs. CRISPLD2 is expressed in both
normal and COPD HLF cells. There was no significant
difference between the two groups in expression of
CRISPLD2 (Fig. 4A), or in the expression of IL-8 and IL-
6 (data not shown). This may have resulted from the lim-
ited number of cell lines available to us. To determine the
effect of endogenous CRISPLD2 on proinflammatory
mediators, we knocked down CRISPLD2 with siRNA in
each primary cell line (HLFCRISPLD2siRNA) which was then
compared to the same primary cell line treated with a
nontarget control siRNA (HLFNCsiRNA). The fold change
of gene expression in HLF CRISPLD2siRNA over HLF NCsiRNA
(same cell) were measured as shown in Figure 4B. Knock-
down of endogenous CRISPLD2 significantly increased
mRNA expression of proinflammatory mediators IL-8,
CCL-2, and IL-6, in both normal and COPD adult lung
fibroblast (4 normal and 4 COPD), revealing that
CRISPLD2 has intrinsic antiinflammatory properties,
reducing production of proinflammatory cytokines.
RNA-Seq transcriptome profiling of
HFLCRISPLD2siRNA primary cells
To identify transcriptomic changes following CRISPLD2
suppression in primary lung fibroblasts, we performed
RNA-seq expression profiling of primary HLFs from four
healthy (age: 65–77 years, male) and four COPD human
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Figure 3. rCRISPLD2 suppressed lipopolysaccharide (LPS)-induced inflammation in lung airway epithelial 1HAEo-cells. (A) Activity of rCRISPLD2
after purification was evaluated by transwell migration assay. 1HAEo- cell migration (%) was significantly increased in the presence of
rCRISPLD2 at indicated amounts in a dose-dependent manner. CRISPLD2-conditioned medium was used as positive control (PC), nontreated
cells were used as a negative control (NC) (n = 3, *P < 0.05 vs. NC). (B) 1HAEo- cells were treated by LPS (2.5 lg/mL) for 24 h with added
rCRISPLD2 at various doses. (C) By ELISA, rCRISPLD2 also inhibited LPS-induced IL-8 protein secretion from 1HAEo- in a dose-dependent
manner (N = 3,*P < 0.05, **P < 0.01 no LPS vs. LPS, two-way analysis of variance).
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patients (age: 58–68 years, male, moderate-severe COPD,
GOLD classification) transfected with siRNA negative
control (HLF NCsiRNA) or CRISPLD2 knockdown (HLF
CRISPLD2siRNA), in technical duplicates. Out of 65,972
genes, 106 were significantly differentially expressed
between HLF CRISPLD2siRNA and HLF NCsiRNA (Table 2).
Gene ontology analysis of sets of significantly differentially
expressed genes was performed using DAVID 6.7 (da
Huang et al. 2009). These 106 genes were ontologically
enriched for terms related to hormone stimulation
response, apoptosis, focal adhesion, chemokine signaling
pathway, cancer, VEGF signaling, cell development, and
differentiation (Table 1). Many of these functional
pathways have been previously associated with CRISPLD2
(Kaplan et al. 1999; Oyewumi et al. 2003a, 2003b; Nadeau
et al. 2006; Quinlan et al. 2007; Lan et al. 2009; Wang
et al. 2009, 2013; Shen et al. 2011; Yoo et al. 2014; Zhang
et al. 2015). The complete set of differentially expressed
genes is described in Table 2. Transcriptomic changes in
these functional groups were observed in both normal
and COPD lung fibroblasts in which CRISPLD2 was sup-
pressed. There were no significant differences in the gene
profile affected in the two groups.
Discussion
Fibroblasts have been recognized as emerging effector cells
in chronic inflammation. They arise from monocyte pre-
cursors and preserve both the inflammatory features of
macrophages and the tissue remodeling properties of
fibroblasts. Fibroblasts have been implicated in the patho-
genesis of chronic inflammatory states involving the lung,
autoimmunity, liver, skin, and normal aging (Reilkoff
et al. 2011).
In this study, we demonstrated that CRISPLD2, an
antiinflammatory mediator released from pulmonary
fibroblasts, directly inhibited inflammation in lung fibrob-
lasts and epithelial cells through mesenchymal–epithelial
interactions. Knockdown of CRISPLD2 in fetal lung
MRC5 fibroblasts augmented levels of the proinflamma-
tory mediator IL-8 in LPS-induced inflammation (Fig. 2).
The protective effect of CRISPLD2 against proinflamma-
tory mediators was also demonstrated in adult primary
lung HLF cells (Fig. 4).
We previously reported that in rat fetal lung,
CRISPLD2 is secreted by the fibroblasts located adjacent
to the airway epithelium, and is concentrated at the tips
of budding alveoli (Nadeau et al. 2006). In this study, we
show that rCRISPLD2 protein has a direct effect on lung
epithelial cell migration (Fig. 3A) and also inhibits LPS-
induced lung epithelial cell inflammation (Fig. 3B). Thus,
the pulmonary fibroblast can contribute directly to pul-
monary inflammation and ultimately to airway wall
remodeling by releasing mediators that have profound
effects on the surrounding environment. These mediators
are interrelated and balanced to play an important role in
regulating cell functions such as proliferation, migration
and ECM deposition and remodeling within the lung
(Chapman 2011). The IL-6 family may promote ECM
remodeling via activation of matrix metalloproteinases
(MMPs) (Chapman 2011).
Our data are in accord with other findings demonstrat-
ing antiinflammatory properties of CRISPLD2. Recent
studies in humans and rodents attribute antiinflammatory
properties to CRISPLD2 /Crispld2. For example, Crispld2
directly binds to LPS and inhibits LPS binding to TLR4
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Figure 4. Knockdown of CRISPLD2 augmented inflammation in
primary adult human lung fibroblasts. (A) endogenous expression of
CRISPLD2 mRNA in primary normal and chronic obstructive
pulmonary disease HLFs (N = 5, P > 0.05). (B) CRISPLD2 was
knocked down with siCRISPLD2 in HLFs (HLFCRISPLD2siRNA). A
HLFNCsiRNA control cell line was generated to be used as a control
for each primary cell line. The fold change of gene expression in
HLFCRISPLD2siRNA over HLFNCsiRNA from the same cell line are
indicated in Figure 4B. CRISPLD2 expression was reduced by 80%
when HLFCRISPLD2siRNA cells were compared to HLFNCsiRNA cells
(indicated as the dot line). IL-8, IL6, CCL-2 increased significantly in
HLFCRISPLD2siRNA (N = 4, *P < 0.05, fold change of HLFCRISPLD2siRNA
over HLFNCsiRNA from the same cells).
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and consequently reduces LPS-derived inflammation.
Upregulation of the serum soluble form of Crispld2 pro-
tected mice against LPS-induced lethality (Wang et al.
2009). Low-serum CRISPLD2 level may predict a poor
outcome in patients with sepsis or septic shock (Wang
et al. 2013). CRISPLD2 knockdown increased IL-6 and
IL-8 levels in airway smooth muscle cells induced by IL-
1b (Himes et al. 2014).
Table 1. Functional annotation clusters obtained with the NIH DAVID tool using differentially expressed genes.
Category Term Count P-value
Annotation cluster 1 Enrichment score: 2.09
GOTERM_BP_FAT GO:0009725 – response to hormone stimulus 9 4.86E-04
GOTERM_BP_FAT GO:0009719 – response to endogenous stimulus 9 9.25E-04
GOTERM_BP_FAT GO:0010033 – response to organic substance 11 0.003059
GOTERM_BP_FAT GO:0032870 – cellular response to hormone stimulus 5 0.004473
GOTERM_BP_FAT GO:0007242 – intracellular signaling cascade 12 0.047661
GOTERM_BP_FAT GO:0048545 – response to steroid hormone stimulus 4 0.072211
GOTERM_BP_FAT GO:0019932 – second-messenger-mediated signaling 4 0.114472
Annotation cluster 2 Enrichment score: 1.78
KEGG_PATHWAY hsa04062: Chemokine signaling pathway 7 0.00177
GOTERM_BP_FAT GO:0032870 – cellular response to hormone stimulus 5 0.004473
GOTERM_BP_FAT GO:0007169 – transmembrane receptor protein tyrosine kinase signaling pathway 6 0.005324
GOTERM_BP_FAT GO:0007167 – enzyme linked receptor protein signaling pathway 7 0.007334
GOTERM_BP_FAT GO:0008286 – insulin receptor signaling pathway 3 0.014805
GOTERM_BP_FAT GO:0043434 – response to peptide hormone stimulus 4 0.042374
GOTERM_BP_FAT GO:0032869 – cellular response to insulin stimulus 3 0.045857
GOTERM_BP_FAT GO:0032868 – response to insulin stimulus 3 0.09006
KEGG_PATHWAY hsa04914: Progesterone-mediated oocyte maturation 3 0.123218
Annotation cluster 3 Enrichment score: 1.35
KEGG_PATHWAY hsa04062: Chemokine signaling pathway 7 0.00177
KEGG_PATHWAY hsa05222: Small cell lung cancer 5 0.002729
GOTERM_BP_FAT GO:0007169 – transmembrane receptor protein tyrosine kinase signaling pathway 6 0.005324
GOTERM_BP_FAT GO:0007167 – enzyme linked receptor protein signaling pathway 7 0.007334
KEGG_PATHWAY hsa04210: Apoptosis 4 0.023003
KEGG_PATHWAY hsa04510: Focal adhesion 5 0.052017
KEGG_PATHWAY hsa05200: Pathways in cancer 6 0.078927
KEGG_PATHWAY hsa04370: VEGF signaling pathway 3 0.098097
KEGG_PATHWAY hsa05210: Colorectal cancer 3 0.118536
KEGG_PATHWAY hsa04012: ErbB signaling pathway 3 0.125576
KEGG_PATHWAY hsa04810: Regulation of actin cytoskeleton 4 0.193564
KEGG_PATHWAY hsa04670: Leukocyte transendothelial migration 3 0.203014
GOTERM_BP_FAT GO:0007166 – cell surface receptor linked signal transduction 13 0.216222
GOTERM_CC_FAT GO:0005829 – cytosol 8 0.586609
Annotation cluster 4 Enrichment score: 1.31
KEGG_PATHWAY hsa05222: Small cell lung cancer 5 0.002729
KEGG_PATHWAY hsa05223: Non-small cell lung cancer 3 0.055422
KEGG_PATHWAY hsa05214: Glioma 3 0.072728
KEGG_PATHWAY hsa05200: Pathways in cancer 6 0.078927
KEGG_PATHWAY hsa05218: Melanoma 3 0.08938
KEGG_PATHWAY hsa05212: Pancreatic cancer 3 0.091537
KEGG_PATHWAY hsa05220: Chronic myeloid leukemia 3 0.098097
Annotation cluster 5 Enrichment score: 1.27
GOTERM_BP_FAT GO:0055002 – striated muscle cell development 3 0.028091
GOTERM_BP_FAT GO:0055001 – muscle cell development 3 0.03221
GOTERM_BP_FAT GO:0051146 – striated muscle cell differentiation 3 0.072328
GOTERM_BP_FAT GO:0042692 – muscle cell differentiation 3 0.123692
Clusters with enrichment scores >1.0 are shown. Individual P-values listed correspond to EASE Scores, or modified Fisher exact P-values com-
puted by DAVID.
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Table 2. List of differentially expressed genes.
Gene_short_
name
Sig_Norm_ P < 0.05_
2fold (strict)
RankSum_
Pval_Norm
Log2Fold_
Norm
Sig_COPD_
P < 0.05_2fold
RankSum_
Pval_COPD
Log2Fold_
COPD
CRISPLD2 1* 0.000155 2.21 1 0.000622 1.77
SAMD15 1 0.000155 1.18 1 0.000155 1.38
RASSF8 1 0.000155 1.36 1 0.000155 1.15
HMGB2 0* 0.028127 0.95 1 0.000155 1.07
SNX4 0 0.000155 0.97 1 0.000155 1.12
ULBP2 1 0.020668 1.17 1 0.020668 1.00
ISY1 0 0.000155 0.93 1 0.000155 1.09
AP000275.65 0 0.046309 0.30 1 0.001088 1.04
GALNT4 1 0.000155 1.26 1 0.000155 1.07
LEPROTL1 0 0.000155 0.91 1 0.000155 1.03
ACTG2 0 0.000622 0.96 1 0.001865 1.03
LRRIQ1 0 0.000622 0.67 1 0.000155 1.04
TMEM67 1 0.000155 1.09 0 0.000155 0.99
DCP1A 1 0.000155 1.15 1 0.000155 1.04
POC1B-GALNT4 0 0.38228 0.45 1 0.028127 1.07
KCTD9 1 0.000155 1.06 0 0.000155 0.98
KCTD9P4 1 0.000155 1.16 0 0.000155 0.82
TSC22D2 1 0.000155 1.05 0 0.000155 0.99
KCTD9P2 1 0.000155 1.06 0 0.000155 0.83
SERTAD2 1 0.004662 1.00 0 0.000155 0.64
RP11-512M8.5 2* 0.004196 1.19 0 1 0.04
ZCCHC10 2 0.000155 1.01 0 0.000155 0.74
PSMB9 2 0.000311 1.04 0 0.000311 0.94
FAM26E 2 0.000155 1.02 0 0.001865 0.94
APOL3 2 0.000155 1.07 0 0.000155 0.95
SCO1 2 0.000155 1.00 0 0.000155 0.89
IL15RA 2 0.001088 1.13 0 0.000155 0.98
B3GNT5 2 0.000155 1.01 0 0.000155 0.92
SLC41A2 0 0.000155 0.71 2 0.000155 1.00
RP2 2 0.000155 1.04 0 0.000155 0.99
C3 2 0.010412 1.30 2 0.001865 1.08
MPP5 2 0.000155 1.01 0 0.000155 0.95
CXCL8 0 0.57374 0.47 2 0.010412 1.01
NBN 2 0.000155 1.12 0 0.000155 0.98
STK17B 2 0.000155 1.09 0 0.000155 0.99
SLC9A6 2 0.000155 1.05 2 0.000155 1.03
LRRC58 2 0.000155 1.22 0 0.000155 0.97
CPOX 0 0.000155 0.91 2 0.000155 1.02
CYCS 2 0.000155 1.14 2 0.000155 1.04
PCGF5 2 0.000155 1.06 0 0.000155 0.99
C12orf49 0 0.000155 1.00 2 0.000155 1.01
GPR180 2 0.000155 1.02 2 0.000155 1.04
ENPP5 0 0.049883 0.95 2 0.010412 1.11
IRAK2 0 0.001865 0.90 2 0.002953 1.01
CCL2 0 0.38228 0.87 2 0.010412 1.16
MEST 2 0.006993 1.10 2 0.000155 1.06
RP11-554I8.2 0 0.000311 0.95 2 0.014763 1.12
ARSI 0 0.002953 0.81 2 0.004662 1.10
PIK3R3 0 0.020668 0.94 2 0.004662 1.08
SPIN4 2 0.001865 1.06 0 0.000155 0.94
CDK6 0 0.000155 0.84 2 0.000155 1.01
GNB4 2 0.000155 1.35 2 0.000155 1.11
SDPR 2 0.037918 1.22 2 0.000155 1.09
POMK 0 0.000155 0.90 2 0.000155 1.02
(Continued)
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Table 2. Continued.
Gene_short_
name
Sig_Norm_ P < 0.05_
2fold (strict)
RankSum_
Pval_Norm
Log2Fold_
Norm
Sig_COPD_
P < 0.05_2fold
RankSum_
Pval_COPD
Log2Fold_
COPD
INIP 2 0.000155 1.13 2 0.000155 1.12
ADCY7 0 0.001865 0.94 2 0.000155 1.04
PSD3 2 0.000155 1.07 2 0.000155 1.09
AC007620.3 2 0.000155 1.49 2 0.000155 1.24
PLAG1 0 0.000155 0.91 2 0.000311 1.12
CTC-444N24.7 0 0.000155 0.85 2 0.000155 1.01
PDCD4 2 0.000155 1.19 2 0.000155 1.19
BLOC1S6 2 0.000155 1.22 2 0.000155 1.09
PLAU 0 0.037918 0.82 2 0.000155 1.18
ENO1P4 0 0.1049 0.54 2 0.000155 1.36
KRT19 0 0.1049 0.69 2 0.049883 1.20
CTC-444N24.11 0 0.000155 0.92 2 0.000155 1.06
RASA2 2 0.000155 1.25 2 0.000155 1.20
ZNF460 0 0.000155 0.91 2 0.000155 1.05
PMAIP1 2 0.000622 1.35 2 0.001865 1.28
SLC4A4 0 0.082984 1.11 2 0.001865 1.17
HINT3 2 0.000155 1.28 2 0.000155 1.27
ARSJ 2 0.000155 1.42 2 0.000155 1.27
EFHD2 2 0.000155 1.31 2 0.000155 1.22
ELMOD2 2 0.000155 1.50 2 0.000155 1.35
PAWR 2 0.000155 1.44 2 0.000155 1.29
PIK3R1 2 0.000155 1.23 2 0.001865 1.24
FAM46A 2 0.001865 1.29 2 0.000155 1.31
NAP1L5 2 0.000155 1.34 2 0.000155 1.39
ARL5B 2 0.000155 1.49 2 0.000155 1.32
LINC00707 0 0.037918 0.81 2 0.000155 1.21
ABCB10 2 0.000155 1.31 2 0.000155 1.34
CNOT6 2 0.000155 1.14 2 0.000155 1.25
LCLAT1 2 0.000155 1.60 2 0.000155 1.40
TBC1D5 2 0.000155 1.26 2 0.000155 1.34
HIPK2 0 0.000155 0.80 2 0.000155 1.15
C4orf32 2 0.000155 1.41 2 0.000155 1.42
RP11-101E13.5 2 0.000155 1.46 2 0.000155 1.43
AKIRIN1 2 0.000155 1.47 2 0.000155 1.46
CPA4 2 0.000155 1.44 2 0.000155 1.50
PDHX 2 0.000155 1.67 2 0.000155 1.52
ITGB8 2 0.000155 1.34 2 0.037918 1.51
PTK2 2 0.000155 1.41 2 0.000155 1.48
SYNPO 2 0.014763 1.28 2 0.000155 1.33
SETD7 2 0.000155 1.43 2 0.000155 1.51
CAV2 2 0.000155 1.75 2 0.000155 1.59
CLDN12 2 0.000155 1.45 2 0.000155 1.56
TROVE2 2 0.000155 1.70 2 0.000155 1.57
GNPNAT1 2 0.000155 1.77 2 0.000155 1.58
TULP3 2 0.000155 1.69 2 0.000155 1.66
UBE2V2 2 0.000155 1.72 2 0.000155 1.63
AGPAT9 2 0.001865 1.53 2 0.000155 1.65
EIF4EBP2 2 0.000155 1.28 2 0.000155 1.49
LPP 2 0.000155 1.44 2 0.000155 1.51
UHMK1 2 0.000155 1.81 2 0.000155 1.76
MMP1 2 0.037918 2.11 2 0.001865 2.26
CXCL5 2 0.010256 1.89 2 0.020668 1.89
C9orf41 2 0.000155 1.90 2 0.000155 1.85
A total of 106 genes significantly differentially expressed between HLF CRISPLD2siRNA and HLF NCsiRNA (in Norm or COPD, N = 8, four Norm
and four COPD, P < 0.05 and log2 fold magnitude >1 that is, twofold). COPD, chronic obstructive pulmonary disease. *2 = sig up in silenced
/ nonsilenced; *1 = sig down in silenced/nonsilenced; *0 = not sig
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Cytokines can regulate cellular responses to inflamma-
tion both reversibly (e.g., synthesis/secretion of specific
proteins) and irreversibly (e.g., cell division or apoptosis),
through the coordinated effects of positive and negative
signals. Cytokines modulate airway remodeling and fibro-
sis in respiratory diseases such as BPD, COPD, asthma,
and interstitial lung diseases (Chapman 2011). Our pre-
sent findings suggest that CRISPLD2 is involved in the
regulation of endotoxin-induced inflammatory responses
of lung fibroblasts and epithelial cells, and support the
attribution to CRISPLD2 of a role in airway remodeling
through mesenchymal–epithelial interactions.
Our findings are consistent with earlier work demon-
strating a role for CRISPLD2 in antiinflammatory signal-
ing in the lung. We showed previously that Crispld2
mRNA expression is upregulated in rat fetal lung fibro-
blasts in response to GCs (Kaplan et al. 1999; Himes
et al. 2014). More recently, using RNA-seq profiling, we
(STW) identified CRISPLD2 as a GC-responsive gene that
modulates cytokine function in airway smooth muscle
cells (ASM) (Himes et al. 2014). In a search for the
mechanism of action of GC-responsive genes that sup-
press inflammation in asthma, Himes et al. identified
CRISPLD2 as a GC target. CRISPLD2 expression was also
induced by IL-1b and siRNA-mediated knockdown of
CRISPLD2 increased IL-1b induced expression of IL-6
and IL-8 in ASM cells (Himes et al. 2014). These findings
suggested that CRISPLD2 may have therapeutic potential
in asthma.
We found that silencing of CRISPLD2 impacted tran-
scriptomic changes related to multiple cell functions
including hormone stimulation response, apoptosis, focal
adhesion, chemokine signaling pathway, cancer, VEGF
signaling, cell development, and differentiation in human
lung fibroblasts (Table 1). Of interest, these effects were
found in normal cells as well as in cells isolated from
lungs of patients with COPD. In recent work directed at
identifying potential therapeutic strategies for treatment
of COPD, Greer et al. investigated the potential coopera-
tive effects of adenosine A2B receptor agonists and GCs as
antiinflammatory agents in BEAS 2B cells (Greer et al.
2013). Among the antiinflammatory genes induced in
these cells was CRISPLD2. Our RNA-seq results confirm
the efficiency of CRISPLD2 knockdown and support the
functional roles of CRISPLD2 in extracellular matrix
development and function, and in inflammation. The
extent of its role as an antiinflammatory mediator in
COPD, however, remains unclear. Clearly, the effects of
CRISPLD2 suppression may induce similar transcriptomic
changes in lung fibroblasts and yet contribute to even
more profound effects on the phenotype of COPD
patients. It is also important to note that if CRISPLD2
has antiinflammatory effects – even if it is not a primary
inducer of inflammation in COPD – it may still have
potential as a broad-spectrum therapeutic agent in the
treatment of lung inflammation in COPD and other lung
pathologies.
Conclusion
Our studies support the hypothesis that suppression of
CRISPLD2 increases the risk of lung inflammation in
early life and in adulthood. CRISPLD2 serves as an
endogenous antiinflammatory protein which can curtail
proinflammatory signaling by lung epithelial cells through
mesenchymal–epithelial interactions. Further investigation
of the potential of CRISPLD2 to serve as a therapeutic
candidate is imperative.
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